Aquestive Reconciled Depreciation vs Total Revenue Analysis

AQST Stock

USD 5.09 0.07 1.36%

Aquestive Therapeutics financial indicator trend analysis is way more than just evaluating Aquestive Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aquestive Therapeutics is a good investment. Please check the relationship between Aquestive Therapeutics Reconciled Depreciation and its Total Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.

Reconciled Depreciation vs Total Revenue

Reconciled Depreciation vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aquestive Therapeutics Reconciled Depreciation account and Total Revenue. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Aquestive Therapeutics' Reconciled Depreciation and Total Revenue is -0.07. Overlapping area represents the amount of variation of Reconciled Depreciation that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Aquestive Therapeutics, assuming nothing else is changed. The correlation between historical values of Aquestive Therapeutics' Reconciled Depreciation and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Reconciled Depreciation of Aquestive Therapeutics are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Reconciled Depreciation i.e., Aquestive Therapeutics' Reconciled Depreciation and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.07

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Aquestive Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Aquestive Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aquestive Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aquestive Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.At this time, Aquestive Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 257.2 K in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 8.5 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	35.8M	28.3M	29.8M	31.9M
Total Revenue	50.8M	47.7M	50.6M	48.2M

Gross Profit Total Revenue

Aquestive Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Inventory	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Other Liab	Cash And Short Term Investments	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total
Total Assets		0.77	0.76	-0.22	0.29	-0.38	0.88	0.96	0.23	0.64	0.27	0.58	0.57	-0.49	0.99	-0.44	-0.34	-0.82	-0.34	0.3	0.88	-0.79	-0.67	0.04	-0.8	-0.55
Other Current Liab	0.77		0.82	-0.67	-0.07	-0.74	0.51	0.67	0.71	0.38	0.08	0.62	0.87	-0.53	0.72	-0.47	-0.14	-0.87	-0.64	0.68	0.6	-0.87	-0.87	0.25	-0.49	-0.03
Total Current Liabilities	0.76	0.82		-0.53	0.01	-0.57	0.73	0.75	0.5	0.32	-0.13	0.74	0.76	-0.38	0.74	-0.37	0.02	-0.77	-0.42	0.52	0.69	-0.75	-0.74	0.39	-0.52	-0.26
Total Stockholder Equity	-0.22	-0.67	-0.53		0.56	0.98	0.0	-0.12	-0.46	0.01	0.09	-0.63	-0.87	0.37	-0.17	0.33	-0.43	0.59	0.63	-0.97	-0.08	0.61	0.77	-0.71	0.0	-0.33
Net Tangible Assets	0.29	-0.07	0.01	0.56		0.52	0.31	0.5	-0.09	-0.09	-0.28	-0.32	-0.34	-0.54	0.38	-0.44	-0.01	-0.25	-0.24	-0.4	0.63	-0.17	0.0	-0.51	-0.56	-0.54
Retained Earnings	-0.38	-0.74	-0.57	0.98	0.52		-0.12	-0.25	-0.43	-0.16	-0.06	-0.67	-0.91	0.4	-0.32	0.34	-0.3	0.67	0.61	-0.96	-0.18	0.69	0.82	-0.66	0.11	-0.21
Accounts Payable	0.88	0.51	0.73	0.0	0.31	-0.12		0.89	-0.05	0.54	0.11	0.63	0.33	-0.26	0.88	-0.32	-0.29	-0.56	-0.05	0.07	0.82	-0.58	-0.4	0.09	-0.79	-0.62
Cash	0.96	0.67	0.75	-0.12	0.5	-0.25	0.89		0.18	0.51	0.04	0.5	0.45	-0.6	0.98	-0.58	-0.2	-0.81	-0.41	0.22	0.98	-0.79	-0.65	0.02	-0.86	-0.63
Other Assets	0.23	0.71	0.5	-0.46	-0.09	-0.43	-0.05	0.18		0.07	-0.12	0.11	0.58	-0.27	0.19	-0.24	-0.11	-0.45	-0.56	0.38	0.15	-0.42	-0.55	0.03	0.06	0.26
Long Term Debt	0.64	0.38	0.32	0.01	-0.09	-0.16	0.54	0.51	0.07		0.75	0.22	0.23	0.13	0.63	0.03	-0.72	-0.26	0.15	-0.06	0.36	-0.22	-0.3	-0.14	-0.17	-0.58
Net Receivables	0.27	0.08	-0.13	0.09	-0.28	-0.06	0.11	0.04	-0.12	0.75		0.02	0.06	0.33	0.23	0.48	-0.72	0.04	0.38	-0.15	-0.11	0.15	0.05	-0.32	0.12	-0.26
Inventory	0.58	0.62	0.74	-0.63	-0.32	-0.67	0.63	0.5	0.11	0.22	0.02		0.79	-0.21	0.54	-0.28	0.11	-0.57	-0.26	0.61	0.4	-0.66	-0.57	0.7	-0.44	-0.13
Total Liab	0.57	0.87	0.76	-0.87	-0.34	-0.91	0.33	0.45	0.58	0.23	0.06	0.79		-0.44	0.52	-0.39	0.13	-0.77	-0.63	0.83	0.37	-0.79	-0.86	0.61	-0.25	0.03
Short Long Term Debt	-0.49	-0.53	-0.38	0.37	-0.54	0.4	-0.26	-0.6	-0.27	0.13	0.33	-0.21	-0.44		-0.54	0.8	-0.41	0.83	0.89	-0.53	-0.71	0.77	0.72	-0.08	0.62	0.21
Total Current Assets	0.99	0.72	0.74	-0.17	0.38	-0.32	0.88	0.98	0.19	0.63	0.23	0.54	0.52	-0.54		-0.48	-0.31	-0.81	-0.36	0.25	0.92	-0.78	-0.66	0.02	-0.81	-0.63
Short Term Debt	-0.44	-0.47	-0.37	0.33	-0.44	0.34	-0.32	-0.58	-0.24	0.03	0.48	-0.28	-0.39	0.8	-0.48		-0.33	0.66	0.82	-0.45	-0.68	0.77	0.68	-0.32	0.55	0.26
Intangible Assets	-0.34	-0.14	0.02	-0.43	-0.01	-0.3	-0.29	-0.2	-0.11	-0.72	-0.72	0.11	0.13	-0.41	-0.31	-0.33		-0.14	-0.46	0.49	-0.05	-0.13	-0.21	0.55	0.06	0.26
Common Stock	-0.82	-0.87	-0.77	0.59	-0.25	0.67	-0.56	-0.81	-0.45	-0.26	0.04	-0.57	-0.77	0.83	-0.81	0.66	-0.14		0.78	-0.69	-0.81	0.95	0.92	-0.24	0.68	0.27
Property Plant Equipment	-0.34	-0.64	-0.42	0.63	-0.24	0.61	-0.05	-0.41	-0.56	0.15	0.38	-0.26	-0.63	0.89	-0.36	0.82	-0.46	0.78		-0.71	-0.5	0.77	0.84	-0.3	0.32	0.0
Other Liab	0.3	0.68	0.52	-0.97	-0.4	-0.96	0.07	0.22	0.38	-0.06	-0.15	0.61	0.83	-0.53	0.25	-0.45	0.49	-0.69	-0.71		0.21	-0.71	-0.8	0.65	-0.19	0.3
Cash And Short Term Investments	0.88	0.6	0.69	-0.08	0.63	-0.18	0.82	0.98	0.15	0.36	-0.11	0.4	0.37	-0.71	0.92	-0.68	-0.05	-0.81	-0.5	0.21		-0.78	-0.64	0.0	-0.87	-0.64
Short Long Term Debt Total	-0.79	-0.87	-0.75	0.61	-0.17	0.69	-0.58	-0.79	-0.42	-0.22	0.15	-0.66	-0.79	0.77	-0.78	0.77	-0.13	0.95	0.77	-0.71	-0.78		0.9	-0.4	0.72	0.19
Property Plant And Equipment Net	-0.67	-0.87	-0.74	0.77	0.0	0.82	-0.4	-0.65	-0.55	-0.3	0.05	-0.57	-0.86	0.72	-0.66	0.68	-0.21	0.92	0.84	-0.8	-0.64	0.9		-0.44	0.4	0.2
Current Deferred Revenue	0.04	0.25	0.39	-0.71	-0.51	-0.66	0.09	0.02	0.03	-0.14	-0.32	0.7	0.61	-0.08	0.02	-0.32	0.55	-0.24	-0.3	0.65	0.0	-0.4	-0.44		0.02	0.12
Net Debt	-0.8	-0.49	-0.52	0.0	-0.56	0.11	-0.79	-0.86	0.06	-0.17	0.12	-0.44	-0.25	0.62	-0.81	0.55	0.06	0.68	0.32	-0.19	-0.87	0.72	0.4	0.02		0.37
Non Current Assets Total	-0.55	-0.03	-0.26	-0.33	-0.54	-0.21	-0.62	-0.63	0.26	-0.58	-0.26	-0.13	0.03	0.21	-0.63	0.26	0.26	0.27	0.0	0.3	-0.64	0.19	0.2	0.12	0.37

Click cells to compare fundamentals

Aquestive Therapeutics Account Relationship Matchups

Aquestive Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	78.5M	62.9M	62.0M	55.7M	57.4M	57.8M
Other Current Liab	5.5M	9.7M	9.6M	8.8M	7.1M	6.8M
Total Current Liabilities	18.6M	21.1M	22.0M	39.7M	18.3M	20.0M
Total Stockholder Equity	(6.1M)	(48.5M)	(82.1M)	(118.6M)	(106.5M)	(101.2M)
Net Tangible Assets	(6.3M)	(48.6M)	(82.2M)	(120.0M)	(108.0M)	(102.6M)
Retained Earnings	(130.5M)	(186.3M)	(256.8M)	(311.2M)	(319.1M)	(303.1M)
Accounts Payable	12.3M	7.1M	8.3M	9.9M	8.9M	9.4M
Cash	49.3M	31.8M	28.0M	27.3M	23.9M	29.0M
Other Assets	286K	7.8M	6.9M	6.5M	1.0	0.95
Long Term Debt	60.3M	34.3M	51.6M	33.4M	27.5M	41.5M
Net Receivables	13.1M	7.0M	12.1M	4.7M	8.5M	7.7M
Inventory	2.9M	2.5M	4.0M	5.8M	6.8M	3.9M
Total Liab	84.6M	111.4M	144.1M	174.2M	163.9M	98.0M
Total Current Assets	68.3M	44.6M	47.3M	39.9M	41.0M	42.4M
Intangible Assets	153K	102K	51K	1.4M	1.3M	1.3M
Common Stock	34K	35K	41K	55K	69K	65.6K
Property Plant Equipment	9.7M	6.9M	5.1M	7.9M	7.1M	7.7M
Other Liab	5.7M	53.1M	68.7M	97.6M	112.2M	117.8M
Cash And Short Term Investments	49.3M	31.8M	28.0M	27.3M	23.9M	32.1M
Short Long Term Debt Total	60.3M	40.5M	56.4M	56.1M	33.3M	49.9M
Property Plant And Equipment Net	9.7M	10.3M	7.8M	7.9M	9.7M	8.6M
Current Deferred Revenue	806K	693K	765K	1.5M	1.6M	1.1M
Net Debt	11.0M	8.7M	28.4M	28.8M	9.4M	13.1M
Non Current Assets Total	10.2M	18.3M	14.7M	15.8M	16.5M	16.4M
Non Currrent Assets Other	286K	7.8M	6.9M	6.5M	5.4M	4.0M
Common Stock Shares Outstanding	25.4M	33.7M	38.1M	48.7M	61.3M	37.4M
Liabilities And Stockholders Equity	78.5M	62.9M	62.0M	55.7M	57.4M	66.8M
Non Current Liabilities Total	66.0M	90.3M	122.2M	134.6M	145.6M	96.6M
Other Current Assets	3.0M	6.8M	6.2M	2.1M	1.9M	3.0M
Other Stockholder Equity	124.3M	137.7M	174.6M	192.6M	212.5M	142.2M
Property Plant And Equipment Gross	9.7M	10.3M	7.8M	7.9M	52.6M	55.3M
Net Invested Capital	54.2M	(11.6M)	(28.6M)	(66.4M)	(79.0M)	(75.0M)
Net Working Capital	49.8M	23.5M	25.3M	209K	22.7M	20.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC